The efficacy of adjunctive Garcinia mangostana Linn. (mangosteen) pericarp for the treatment of schizophrenia: A 24-week double blind randomised placebo controlled trial

niversity Hospital-Barwon Health0 个研究点目标入组 150 人开始时间: 2016年6月30日最近更新: 2020年5月25日

适应症

试验速览

暂无简介。

•1. Being 18 years or older
•2. Have a DSM-V diagnosis of schizophrenia or schizoaffective disorder.
•3. Score greater than or equal to 54 on the PANSS total score or have a CGI-S score of greater than or equal to 3.
•4. Participants currently under therapy for schizophrenia or schizoaffective disorder will need to have been on that primary therapy for at least four weeks prior to randomization.
•5. Have the capacity to consent to the study and comply with the procedures.
•6. Be using effective contraception if female, sexually active and childbearing age.
•7. Be able to speak, read, write and understand English language.
•8. Participants will be required to nominate a current treating physician and will not be eligible to enter the study until one is identified.

•1. Participants with a known or suspected active systemic medical disorder.
•2. Individuals who are pregnant or lactating.
•3. Participants currently enrolled in any other intervention study.
•4. Individuals who are intolerant, allergic to or have had an anaphylactic reaction to any of the components of the preparation.
•5. Inability to comply with either the requirements of informed consent or treatment protocol.

发起方

niversity Hospital-Barwon Health